FDA Wants to Hear From Rare-Disease Families: Comments Due December 11

By Lucas Project Foundation

Read the original FDA notice

Families bring knowledge that does not always fit into a test result: what a difficult day looks like, what support helps, and what meaningful progress would change.

FDA is inviting that perspective as it develops its Fit-for-Purpose Rare Disease Framework Initiative, an effort to shape how rare-disease therapies are developed and reviewed. Patients, caregivers, advocates and researchers can contribute. This is a public consultation, not an ALD treatment approval. Read the official notice.

How to take part

The notice sets December 11, 2026 as the deadline. Electronic comments are accepted until 11:59 p.m. Eastern Time that day; paper comments must arrive by the deadline.

Visit Regulations.gov, search FDA-2026-N-12214, and follow the submission instructions. The October 28 meeting has passed, but written comments remain an option.

One place to start is FDA’s question about involving patients and experts in review decisions. You might describe what you wish decision-makers understood about your family’s experience.

Electronic comments and attachments become public. Leave out information you do not want shared. For confidential comments, FDA requires a paper submission with one copy containing the confidential information and a second, redacted copy for public posting. Follow the notice’s labeling and submission instructions.

Source and submission instructions: FDA’s official rare-disease framework notice.

Previous
Previous

Visual Changes in Adult Cerebral ALD: What a Three-Person Study Found

Next
Next

About the ALD Information We Share